Zhejiang Shapuaisi Pharmaceutical (603168.SH) obtained the drug registration certificate for sodium bromfenac eye drops.
SAPAS (603168.SH) announcement, recently, the company has received approval from the National Medical Products Administration to issue bromfenac...
Zhejiang Shapuaisi Pharmaceutical (603168.SH) announced that recently, the company received the "Drug Registration Certificate" for the sodium bromfenac eye drops issued by the National Medical Products Administration. The sodium bromfenac eye drops approved this time are used for symptomatic treatment of inflammatory diseases of the external and anterior parts of the eye: blepharitis, conjunctivitis, scleritis (including superficial scleritis), and postoperative inflammation.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
